Search for cancer cure must not be hostage to Big Pharma
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
An investigation has revealed a black market where expensive cancer drugs, kept unaffordable by Big Pharma's patent monopolies, are being illicitly refilled and sold in India. The editorial advocates for faster regulatory approval of biosimilars and the scaling of indigenous R&D to ensure equitable access to life-saving immunotherapies.
UPSC Perspectives
Economic & IPR Lens
Pharmaceutical giants often create a patent thicket (a dense web of overlapping patents covering minor tweaks, formulations, or delivery mechanisms) to extend their monopoly beyond the standard 20-year core patent life. This anti-competitive practice, known as evergreening, artificially inflates the prices of life-saving drugs like Keytruda, pricing them out of reach for most patients. To protect public health, of the strictly prohibits the patenting of new forms of known substances unless they demonstrate significantly enhanced therapeutic efficacy. This provision acts as a vital shield against corporate monopolies, as famously upheld by the Supreme Court in the Novartis case. India must aggressively leverage these legal safeguards to challenge frivolous patents and clear the way for biosimilars (generic versions of biologic drugs made from living cells). Since biosimilars can reduce costs by up to 70 percent, UPSC aspirants should understand the delicate balance between enforcing Intellectual Property Rights (IPR) under the WTO's TRIPS agreement and utilizing legal flexibilities to ensure affordable public healthcare.
Science & Technology Lens
Immunotherapy represents a major paradigm shift in oncology by harnessing the body's own immune system to identify and destroy malignant cells, offering hope where conventional treatments fail. A prime example of this is (Chimeric Antigen Receptor T-cell), where a patient's T-cells are extracted, genetically engineered in a lab to target cancer-specific antigens, and then reinfused into the body as a living drug. India recently achieved a monumental breakthrough with , the country's first indigenous CAR-T therapy developed through academia-industry collaboration. This success transforms India from being merely the pharmacy of the developing world (focused on chemical generics) into a global hub for cutting-edge biotech innovation. While Western CAR-T treatments cost upwards of Rs 3-4 crore, this domestic innovation brings the cost down to a fraction of that price, democratizing access. Scaling this model requires sustained R&D investment, demonstrating to UPSC candidates how indigenous scientific advancements directly address critical socio-economic challenges like healthcare equity and accessibility.
Governance & Regulatory Lens
The exorbitant pricing of patented cancer drugs has inadvertently spawned a dangerous shadow economy where hospital staff and middlemen recycle and refill used vials with spurious substances to sell to desperate patients. This illicit trade exposes severe systemic vulnerabilities in bio-medical waste disposal and highlights a gross absence of accountability in the pharmaceutical supply chain. To combat this menace, the must enforce stringent track-and-trace mechanisms, such as mandatory QR coding and blockchain-based logistics on all high-value drug packaging, to prevent diversion. Furthermore, because biosimilars are derived from living cells rather than simple chemical synthesis, they demand highly advanced manufacturing capabilities and face a rigorous, time-consuming clinical trial process. The government must establish speedier regulatory pathways that do not compromise on patient safety. Additionally, leveraging state-backed initiatives through bodies like the to provide critical risk-financing for biotech startups will ensure that administrative and financial bottlenecks do not delay the deployment of life-saving treatments.